Lupin Limited (NSE:LUPIN)
India · Delayed Price · Currency is INR 2,283.90
+25.70 (1.14%)
May 15, 2026, 3:29 PM IST
Lupin Revenue
In the fiscal year ending March 31, 2026, Lupin had annual revenue of 279.58B INR with 23.12% growth. Lupin had revenue of 74.75B in the quarter ending March 31, 2026, with 31.89% growth.
Revenue
279.58B
Revenue Growth
+23.12%
P/S Ratio
3.72
Revenue / Employee
11.65M
Employees
24,006
Market Cap
1.04T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 279.58B | 52.50B | 23.12% |
| Mar 31, 2025 | 227.08B | 26.97B | 13.48% |
| Mar 31, 2024 | 200.11B | 33.69B | 20.25% |
| Mar 31, 2023 | 166.42B | 2.36B | 1.44% |
| Mar 31, 2022 | 164.05B | 12.43B | 8.19% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Aurobindo Pharma | 331.82B |
| Cipla | 279.67B |
| Zydus Lifesciences | 260.89B |
| Glenmark Pharmaceuticals | 165.10B |
| Alkem Laboratories | 142.53B |
| Mankind Pharma | 139.14B |
| Divi's Laboratories | 103.14B |
| Ipca Laboratories | 95.06B |
Lupin News
- 8 days ago - Lupin Ltd (BOM:500257) Q4 2026 Earnings Call Highlights: Record Growth Amidst Competitive Challenges - GuruFocus
- 8 days ago - Q4 2026 Lupin Ltd Earnings Call Transcript - GuruFocus
- 9 days ago - Lupin Transcript: Q4 25/26 - Transcripts
- 12 days ago - Lupin secures USFDA approval for rare disease drug with $337 million opportunity - Business Upturn
- 25 days ago - Lupin launches Dapagliflozin and Metformin Extended-Release Tablets in the U.S. after FDA approval - Business Upturn
- 6 weeks ago - Lupin Receives Tentative U.S. FDA Approval For Sugammadex Injection - Nasdaq
- 6 weeks ago - Lupin receives tentative approval from U.S. FDA for Sugammadex Injection - Business Upturn
- 6 weeks ago - Lupin subsidiary Nanomi increases stake in Multicare Pharmaceuticals Philippines to 56.28% - Business Upturn